532605 Sigma-AldrichAurora A/MYCN Dual Inhibitor, CD532 - CAS 1639009-81-6 - Calbiochem
A cell permeable, highly potent, selective inhibitor of Aurora A (IC₅₀ = 48 nM). Disrupts MYCN-Aurora A complex.
More>> A cell permeable, highly potent, selective inhibitor of Aurora A (IC₅₀ = 48 nM). Disrupts MYCN-Aurora A complex. Less<<Synonyms: Aurora A Inhibitor, CD532, MYCN Inhibitor, CD532
Recommended Products
Overview
Replacement Information |
---|
Key Spec Table
CAS # | Empirical Formula |
---|---|
1639009-81-6 | C₂₆H₂₅F₃N₈O |
Products
Catalogue Number | Packaging | Qty/Pack | |
---|---|---|---|
5.32605.0001 | Glass bottle | 10 mg |
References | |
---|---|
References | Lee, J.K., et al. 2016. Cancer Cell. 29, In press. Gustafson, W. C., et al. 2014. Cancer Cell. 26, 414. |
Product Information | |
---|---|
CAS number | 1639009-81-6 |
Form | Tan solid |
Hill Formula | C₂₆H₂₅F₃N₈O |
Chemical formula | C₂₆H₂₅F₃N₈O |
Reversible | Y |
Quality Level | MQ100 |
Applications |
---|
Biological Information | |
---|---|
Primary Target | Aurora A |
Primary Target IC<sub>50</sub> | 48 nM |
Secondary target | MYCN |
Purity | ≥97% by HPLC |
Physicochemical Information | |
---|---|
Cell permeable | Y |
Dimensions |
---|
Materials Information |
---|
Toxicological Information |
---|
Safety Information according to GHS |
---|
Safety Information |
---|
Product Usage Statements |
---|
Packaging Information | |
---|---|
Packaged under inert gas | Packaged under inert gas |
Transport Information |
---|
Supplemental Information |
---|
Specifications |
---|
Global Trade Item Number | |
---|---|
Catalogue Number | GTIN |
5.32605.0001 | 04055977281804 |
Documentation
Aurora A/MYCN Dual Inhibitor, CD532 - CAS 1639009-81-6 - Calbiochem SDS
Title |
---|
References
Reference overview |
---|
Lee, J.K., et al. 2016. Cancer Cell. 29, In press. Gustafson, W. C., et al. 2014. Cancer Cell. 26, 414. |
Technical Info
Title |
---|
Characterization of Estrogen Receptor α Phosphorylation Sites in Breast Cancer Tissue Using the SNAP i.d® 2.0 System |
White Paper: Further considerations of antibody validation and usage. |